Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.2830400223DOI Listing

Publication Analysis

Top Keywords

change paraprotein
4
paraprotein iga
4
iga chain
4
chain multiple
4
multiple myeloma
4
change
1
iga
1
chain
1
multiple
1
myeloma
1

Similar Publications

Predicting cancer-associated clinical events is challenging in oncology. In Multiple Myeloma (MM), a cancer of plasma cells, disease progression is determined by changes in biomarkers, such as serum concentration of the paraprotein secreted by plasma cells (M-protein). Therefore, the time-dependent behavior of M-protein and the transition across lines of therapy (LoT), which may be a consequence of disease progression, should be accounted for in statistical models to predict relevant clinical outcomes.

View Article and Find Full Text PDF
Article Synopsis
  • * Data from 203 patients from phase I/II clinical trials were used, creating both longitudinal and PFS-specific models that were then integrated into a joint model to capture their interactions.
  • * The final model indicated that serum M-protein changes correlate with PFS and validated the dosing regimen of Isa in a pivotal phase III study, supporting ongoing research and treatment approaches in multiple myeloma. *
View Article and Find Full Text PDF

Nephrotic syndrome (NS) in pregnancy has been associated with poor fetal outcomes. Focal segmental glomerulosclerosis (FSGS) is one of the common causes of NS and can be primary or secondary. However, there are few case reports of FSGS diagnosed in the peripartum period and the approaches to management.

View Article and Find Full Text PDF

Background: Canine vector-borne diseases (VBDs) induce non-specific dysproteinemias, detectable by serum protein electrophoresis (SPE). VBDs have been reported to induce a monoclonal gammopathy pattern. Monoclonal gammopathies are commonly the result of paraprotein (M-protein) produced by an immunoglobulin-secreting neoplasm.

View Article and Find Full Text PDF

Soluble B-cell maturation antigen (sBCMA) is overexpressed on multiple myeloma (MM) cells. We investigated whether sBCMA levels correlated with other myeloma tumor volume indicators and its utility in monitoring oligo-secretory/non-secretory (O-S/Non-S) MM. In 115 patients with newly diagnosed MM, sBCMA was compared with M-protein levels, bone marrow plasma cells (BMPCs), circulating tumor cells (CTCs), and total diffusion volume (tDV; estimated by whole-body diffusion-weighted magnetic resonance imaging) at diagnosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!